Pharmacological inhibition of bacterial β-glucuronidase prevents irinotecan-induced diarrhea without impairing its antitumor efficacy in vivo. [electronic resource]
Producer: 20190513Description: 41-49 p. digitalISSN:- 1096-1186
- Animals
- Antineoplastic Agents, Phytogenic -- therapeutic use
- Bacterial Proteins -- antagonists & inhibitors
- Cell Line, Tumor
- Colonic Neoplasms -- drug therapy
- Diarrhea -- chemically induced
- Escherichia coli -- drug effects
- Eubacterium -- enzymology
- Glucuronidase -- antagonists & inhibitors
- HEK293 Cells
- Humans
- Irinotecan -- therapeutic use
- Male
- Mice, Inbred BALB C
- Peptostreptococcus -- enzymology
- Quinolines -- pharmacology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.